{"prompt": "['REduCing Immunogenicity to PegloticasE (RECIPE)', 'Protocol #Version v12: 13Jan2020', 'pegloticase. Other AEs that occur outside of the 2-hour window following the infusion may also be categorized as an IR', 'per site PI discretion. Signs and symptoms of the IR, and treatments administered, will be documented in the medical', 'record and in the eCRF. Examples of AEs not considered possible IRs include but are not limited to: laboratory', 'abnormalities that are unlikely to have occurred during or within 2 hours following the infusion (e.g., anemia,', 'hypercholesterolemia), gout flares, most infectious diseases, or the recurrence or worsening of a known chronic medical', \"problem identified in the participant's medical history.\", 'IRs are not uncommon when biological agents are administered by IV infusion. Therefore, all participants will receive', 'pre-treatment prophylaxis consisting of at least an antihistamine and corticosteroid prior to each infusion of pegloticase', '(see Table 2). In order to standardize this regimen, participants will take fexofenadine (60 mg, PO) the night before and', 'again on the morning of the infusion with acetaminophen (1000 mg, PO) Prior to the infusion, hydrocortisone (200 mg,', 'IV) will be administered and a at minimum, a targeted physical exam will be performed. The name, dose, route, date,', 'and time of administration of each prophylactic medication will be recorded in the medical record and in the CRF.', 'Table 2. Infusion Reaction Prophylaxis', 'Night Before Infusion', 'Morning of Infusion', 'Following Arrival at Infusion Clinic', 'Participant takes:', 'Participant takes:', 'Abbreviated physical examination to include:', 'Fexofenadine (60 mg) PO', 'Fexofenadine (60 mg) PO', 'Dermatological - Noting Any Rashes', 'Acetaminophen (1000 mg) PO', 'Chest - Noting Breath Sounds', 'Vital Signs', 'Start IV and Administer hydrocortisone (200 mg)', 'Initiate Drug Infusion', '9.3.8.2 PREGNANCY', 'Premenopausal women will have a pregnancy test before the study starts and again throughout the study. If participants', 'suspect that they may have become pregnant during the study, the study coordinator will contact the study PI', 'immediately and the PI or Study Coordinator will instruct the participant to stop taking all study medication. If it is', 'confirmed that the participant is pregnant, they will be withdrawn from the study. The study PI will schedule a follow-up', 'visit and may choose to follow the outcome of the pregnancy. If it is discovered that participants are breastfeeding, they', 'are not eligible to participate in the study and their participation will be discontinued immediately.', '9.4', 'UNANTICIPATED PROBLEMS', '9.4.1 DEFINITION OF UNANTICIPATED PROBLEMS (UP)', 'Unanticipated problems, in general, are defined as any incident, experience, or outcome that meets all of the following', 'criteria:', 'Unexpected (in terms of nature, severity, or frequency) given (a) the research procedures that are described', 'in the protocol-related documents, such as the IRB-approved research protocol and informed consent', 'document; and (b) the characteristics of the participant population being studied;', 'Related or possibly related to participation in the research (in this guidance document, possibly related', 'means there is a reasonable possibility that the incident, experience, or outcome may have been caused by', 'the procedures involved in the research); and', 'Suggests that the research places participants or others at a greater risk of harm (including physical,', 'psychological, economic, or social harm) than was previously known or recognized.', '31']['REduCing Immunogenicity to PegloticasE (RECIPE)', 'Protocol #Version v12: 13Jan2020', '9.4.2 UNANTICIPATED PROBLEM REPORTING', 'To ensure that appropriate steps are taken in a timely manner to protect other participants from avoidable harm, we', 'will adhere to HHS regulations at 46.103(b)(5 and will promptly report unanticipated problems to the IRB, NIAMS, FDA,', 'appropriate institutional officials, any supporting department or agency head (or designee), and OHRP.', 'Unanticipated problems that are serious adverse events should be reported to the IRB, NIAMS, FDA etc.', 'within 24 hours of the investigator becoming aware of the event.', 'Any other unanticipated problem should be reported to the IRB, NIAMS, FDA etc. within 10 business days of', 'the investigator becoming aware of the problem.', '9.4.3 REPORTING UNANTICIPATED PROBLEMS TO PARTICIPANTS', 'Participants will be informed about unanticipated problems, and study-related results on an individual or aggregate', 'level.', '10 STATISTICAL CONSIDERATIONS', '10.1 STATISTICAL HYPOTHESES', 'Primary Efficacy Endpoint(s):', 'Assess the feasibility of a short course of immune modulating therapy with daily mycophenolate mofetil (MMF). We will', 'start to test the hypothesis that MMF for 12 weeks will safely attenuate immunogenicity conferred by pegloticase as', 'determined by the proportion of participants achieving and maintaining a serum urate < to 6 mg/dL through 12 weeks,', 'compared to concurrent controls. After 12 weeks of co-administration, all participants will continue on pegloticase for', 'an additional 12 weeks without combination MMF therapy to evaluate the durability and safety of this approach', 'Primary Safety Endpoint(s):', 'Assess the incidence and types of adverse events /infusion reactions.', 'Secondary Endpoints:', '1) Determine the 6 month durability of immune modulation after discontinuation of the short course of MMF by: a)', 'assessing the absolute change in serum urate from baseline to Week 24, and Week 12 to Week 24, and b) determining', 'the proportion of participants with serum urate < 6 mg/dL through 24 weeks, and Week 12 to Week 24; 2) Identify and', 'characterize the pegloticase immune response by immunoglobulin isotypes (IgG and lgM), specificities, and antibody', 'titer, and 3) Examine patient reported outcomes (PROs) using the National institute of Health (NIH) supported Patient', 'Reported Outcomes Measurement Information System (PROMIS) and Gout Impact Scale (GIS) instruments.', '10.2 SAMPLE SIZE DETERMINATION', 'As a pilot proof of concept study, we are not able to fully power the trial to detect a difference between a rate of 60%', 'success vs the success rate after induction by MMF, which we hypothesize will be 80% or more. If we powered the study', 'with 80% power, 2 sided type I error of 5%, we would require 82 participants per group to demonstrate this difference', 'with a treatment and control group. To ensure resources are not wasted, we will confirm that a future larger study is', \"worth pursuing based on results of this pilot study. We have included a decision table based on Fisher's exact tests to\", 'define how results will inform our decision about a future full scale study (see section 10.4.1).', '10.3 POPULATIONS FOR ANALYSES', 'The analysis population will include all enrolled participants who received at least 1 dose of study medication', '(mycophenolate mofetil or placebo) during treatment period (modified intention to treat, mITT). The protocol', '32']\n\n###\n\n", "completion": "END"}